Showing results (1411-1420 of 1,611) with videos related to

Sort By:
Pageof 162
JAMA Oncology|April 6, 2018
Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast DensityAdam R Brentnall, Jack Cuzick, Diana S M Buist, et al.
JAMA Oncology|May 26, 2018
Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical TrialAndrew J Armstrong, Aseem Anand, Lars Edenbrandt, et al.
JAMA Oncology|May 26, 2018
Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysisBeat Foerster, Carmen Pozo, Mohammad Abufaraj, et al.
JAMA Oncology|May 26, 2018
Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case SeriesAnna Maria Frezza, Robin L Jones, Salvatore Lo Vullo, et al.
JAMA Oncology|May 26, 2018
Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast CancerAllison W Kurian, Kevin C Ward, Ann S Hamilton, et al.
JAMA Oncology|June 7, 2018
Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid TumorsRyan N Ptashkin, Diana L Mandelker, Catherine C Coombs, et al.
JAMA Oncology|June 15, 2018
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical TrialStephen J Luen, Rebecca Asher, Chee Khoon Lee, et al.
JAMA Oncology|June 8, 2018
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast CancerNaoko Matsuda, Xiaoping Wang, Bora Lim, et al.
JAMA Oncology|June 30, 2017
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical TrialsGeorgina V Long, Jeffrey S Weber, James Larkin, et al.
JAMA Oncology|June 30, 2017
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical TrialMaud Toulmonde, Nicolas Penel, Julien Adam, et al.
Pageof 162